Denileukin diftitox, sold under the brand name Ontak among others, is an

anti-cancer medication Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs ( chemotherapeutic agents or alkylating agents) in a standard regimen. Chemotherapy may be given with a cu ...

used for the treatment of adults with

T-cell lymphoma T-cell lymphoma is a rare form of cancerous lymphoma affecting T cell, T-cells. Lymphoma arises mainly from the uncontrolled proliferation of lymphocytes, such as T-cells, and can become cancerous. T-cell lymphoma is categorized under Non-Hodgkin ...

. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining

interleukin-2 Interleukin-2 (IL-2) is an interleukin, which is a type of cytokine signaling molecule forming part of the immune system. It is a 15.5–16 kDa protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) ...

and

diphtheria toxin Diphtheria toxin is an exotoxin secreted mainly by '' Corynebacterium diphtheriae'' but also by ''Corynebacterium ulcerans'' and '' Corynebacterium pseudotuberculosis'', the pathogenic bacterium that causes diphtheria. The toxin gene is enco ...

Medical uses

Denileukin diftitox is

indicated In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis ...

for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Adverse effects

The prescription label contains a

boxed warning In the United States, a boxed warning (sometimes "black box warning", colloquially) is a type of warning that appears near the beginning of the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administratio ...

that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.

Society and culture

Legal status

In 1999, denileukin diftitox was approved by the US

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...

(FDA) for the treatment of

cutaneous T-cell lymphoma Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin lymphomas (which are generally B cell, B-cell-related), CTCL is caused by a mutation of T cells. The ma ...

References

External links

* {{Authority control Antineoplastic drugs Diphtheria